<SEC-DOCUMENT>0001104659-23-090520.txt : 20230811
<SEC-HEADER>0001104659-23-090520.hdr.sgml : 20230811
<ACCEPTANCE-DATETIME>20230811163234
ACCESSION NUMBER:		0001104659-23-090520
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230811
DATE AS OF CHANGE:		20230811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980505495
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-227216
		FILM NUMBER:		231164631

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2323505d1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)<BR>
Registration No. 333-227216<BR>
&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prospectus Supplement<BR>
(To the Prospectus dated September 21, 2018)</B>&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2323505d1_424b5-img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2,750,000 Shares of Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement updates, supersedes and amends certain information
contained in the prospectus dated September 21, 2018 (the &ldquo;Original Prospectus&rdquo;), relating to the disposition, from time to
time, of up to 2,750,000 shares (the &ldquo;Shares&rdquo;) of our common stock, par value $0.00001 per share (the &ldquo;Common Stock&rdquo;)
issuable upon the exercise of outstanding warrants, at an original exercise price of $10.00 per share for Class A Warrants and an original
exercise price of $15.00 per share for Class B Warrants, held by the selling stockholders named in the Original Prospectus (the &ldquo;Existing
Warrants&rdquo;). The Existing Warrants have been amended as described below under &ldquo;Amendments to Existing Warrants.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement should be read in conjunction with the Original
Prospectus, and is qualified by reference to the Original Prospectus, except to the extent that the information presented herein supersedes
the information contained in the Original Prospectus. This prospectus supplement is not complete without, and may only be delivered or
used in connection with, the Original Prospectus, including any amendments or supplements thereto. We may amend or supplement the Original
Prospectus from time to time by filing amendments or supplements as required. You should read the entire Original Prospectus and any amendments
or supplements carefully before you make an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the Nasdaq Global Market under the symbol
&ldquo;PTGX.&rdquo; On August 10, 2023, the last reported sale price of our common stock on the Nasdaq Global Market was $18.80 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk. See
&ldquo;Risk Factors&rdquo; in the Original Prospectus and documents incorporated therein by reference for a discussion of such risk factors,
which factors should be read carefully in connection with an investment in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the
accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENTS TO EXISTING WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement is being filed to disclose the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2023, we entered into warrant side letters (the &ldquo;Warrant
Side Letters&rdquo;) with certain of the selling stockholders under which the Company agreed to allow the Existing Warrants to be exercised
for pre-funded warrants representing the same number of Shares underlying the Existing Warrants with an exercise price of $0.001 per share
(the &ldquo;Pre-Funded Warrants&rdquo;). The form of Pre-Funded Warrants will be filed as an exhibit to our Quarterly Report on Form 10-Q
for the quarter ending September 30, 2023 and incorporated by reference into the registration statement of which this prospectus supplement
forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus supplement dated August 11, 2023
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2323505d1_424b5-img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2323505d1_424b5-img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 4 # 2(  A$! Q$!_\0
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MC'YUSBZ_\974,NBPD$9!\N/_ .+H ]JHKQ"?Q]\3] 4W&K^&XI+5?F=OL[8
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M*\?CGV%<[\=X/M7B'P[;YQYJ.F?3+J*]ITW3K72=.@L+.%8K:! D:*.@']:
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MV,[M-6L<:?AQXV,9MS\1+PP'C.Q]V/KOS^M:_@[X5:/X2O1J)GFOM0 .V:;
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$ '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
